NCT00295308View on ClinicalTrials.gov

Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

November 8, 2005

Study Completion Date

July 30, 2014

Conditions
Opioid-Related Disorders
Interventions
DRUG

Clonidine

clonidine up to 0.3 mg/day oral

DRUG

Placebo

oral capsules daily

Trial Locations (1)

21224

National Institute on Drug Abuse, Baltimore

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH

NCT00295308 - Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients | Biotech Hunter | Biotech Hunter